Luxna Biotech Co., Ltd.
PrivateLast Round
Series C
Extension
Aug 7, 2025
Total Funding Raised
$12.43M
Company Overview
Luxna Biotech Co., Ltd. operates in Healthcare & Life Sciences and is based in Suita. Its latest recorded funding round was a Series C Extension round in August 2025.
Luxna Biotech Co., Ltd. is a biotechnology company that develops oligonucleotide therapeutics based on modified nucleic acid technology licensed from Osaka University.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Luxna Biotech Co., Ltd. Comparables
Compare Luxna Biotech Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SynGenis | 78% | |
| ChemGenes Corporation | 76% | |
| Hongene Biotechnology | 76% |
For institutional investors. Book with your work email.
Luxna Biotech Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Aug 7, 2025 | ||||
| Series C | Sep 6, 2024 | ||||
| Debt | Dec 16, 2021 | ||||
| Series A | Feb 10, 2020 | ||||
| Debt | Nov 1, 2019 | ||||
Seed | Mar 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Luxna Biotech Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kobe University Capital | Series C Extension |
| Shinsei Capital Partners | Debt |
| Mizuho Capital | Debt, Series A |
| 株式会社日本政策金融公庫 | Debt |
| Tohoku University Venture Partners | Series C |
| DCI Partners | Series C |
| 日本ベンチャーキャピタル株式会社 | Debt |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 18, 2026
Monthly visitors increased 156% MoM, reaching 4.3K.
- Mar 16, 2026
Partnered with Inabata to expand GuNA amidite supply.
For institutional investors. Book with your work email.
Luxna Biotech Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Luxna Biotech Co., Ltd.'s valuation, stock price, and market status.
Is Luxna Biotech Co., Ltd. a public or private company?
Luxna Biotech Co., Ltd. is a private company.
What is the current stock price of Luxna Biotech Co., Ltd.?
Luxna Biotech Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Luxna Biotech Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Luxna Biotech Co., Ltd. worth (valuation)?
Valuation information for Luxna Biotech Co., Ltd. is not publicly available.
Can I buy Luxna Biotech Co., Ltd. stock?
Luxna Biotech Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Luxna Biotech Co., Ltd.'s last funding round?
Luxna Biotech Co., Ltd.'s most recent funding round was Series C Extension on August 7, 2025.
Who are the main investors in Luxna Biotech Co., Ltd.?
Key investors in Luxna Biotech Co., Ltd. include DCI Partners, OUVC.
Will Luxna Biotech Co., Ltd. IPO soon?
No public IPO plans have been announced for Luxna Biotech Co., Ltd..
How can I track Luxna Biotech Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Luxna Biotech Co., Ltd.'s shares on secondary markets.